Cargando…

Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination

BACKGROUND: Due to elderly residents, nursing homes/assisted living facilities were the most affected places in COVID-19 pandemic. Besides symptomatic patients, asymptomatic patients were detected during routine screening. AIM: This study aims to determine the factors that affect antibody response a...

Descripción completa

Detalles Bibliográficos
Autores principales: Eren-Kutsoylu, Oya Ozlem, Appak, Ozgur, Nazli-Zeka, Arzu, Omeroglu-Simsek, Gokcen, Tekin, Nil, Bayram, Basak, Sayiner, Ayca Arzu, Tanglay, Nesim, Avkan-Oguz, Vildan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277604/
https://www.ncbi.nlm.nih.gov/pubmed/35829907
http://dx.doi.org/10.1007/s11845-022-03095-7
_version_ 1784746019439771648
author Eren-Kutsoylu, Oya Ozlem
Appak, Ozgur
Nazli-Zeka, Arzu
Omeroglu-Simsek, Gokcen
Tekin, Nil
Bayram, Basak
Sayiner, Ayca Arzu
Tanglay, Nesim
Avkan-Oguz, Vildan
author_facet Eren-Kutsoylu, Oya Ozlem
Appak, Ozgur
Nazli-Zeka, Arzu
Omeroglu-Simsek, Gokcen
Tekin, Nil
Bayram, Basak
Sayiner, Ayca Arzu
Tanglay, Nesim
Avkan-Oguz, Vildan
author_sort Eren-Kutsoylu, Oya Ozlem
collection PubMed
description BACKGROUND: Due to elderly residents, nursing homes/assisted living facilities were the most affected places in COVID-19 pandemic. Besides symptomatic patients, asymptomatic patients were detected during routine screening. AIM: This study aims to determine the factors that affect antibody response and viral shedding in stool samples after natural exposure to the virus in residents and staff who recovered from COVID-19 before the vaccine was available. METHODS: This prospective cross-sectional study was conducted at the nation’s highest-capacity Residential and Nursing Home. Blood samples were collected between December 15, 2020 and January 15, 2021 from participating residents and staff for anti-SARS-CoV-2 antibody testing. Stool samples were obtained for SARS-CoV-2 PCR testing 2 months after COVID-19. The Social Sciences (SPSS) program version 15.0 was used for statistical analysis. The Mann–Whitney U test compared SARS‐CoV‐2 antibody concentration between two groups. RESULTS: Four hundred sixty-four (52.3%) residents and 424 (47.7%) staff participated. Entirely 259 (29.2%) participants were anti-SARS-CoV-2 IgG (+) and 255 (28.7%) were SARS-CoV-2 PCR (+). Both antibody and PCR positivity was detected in 196 (76.9%). In PCR (−) group, 63 (10.0%) participants were SARS-CoV‐2 IgG (+). Antibody titers were found highest in SARS-CoV-2 PCR (+) male residents. SARS-CoV-2 IgG titers were significantly high in SARS-CoV-2 PCR (+) and hospitalized participants regardless of age. Stool samples were obtained from 61(23.9%) participants and were found negative. CONCLUSION: A durable SARS-CoV‐2 IgG antibody response was monitored at least 9 months after the participants were diagnosed with COVID-19. SARS-CoV-2 antibody positivity was detected 76.9% in PCR (+) and 10.0% in PCR (−) participants. Knowing the duration of detectable antibodies is an important finding for developing disease prevention and public health strategies.
format Online
Article
Text
id pubmed-9277604
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-92776042022-07-14 Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination Eren-Kutsoylu, Oya Ozlem Appak, Ozgur Nazli-Zeka, Arzu Omeroglu-Simsek, Gokcen Tekin, Nil Bayram, Basak Sayiner, Ayca Arzu Tanglay, Nesim Avkan-Oguz, Vildan Ir J Med Sci Original Article BACKGROUND: Due to elderly residents, nursing homes/assisted living facilities were the most affected places in COVID-19 pandemic. Besides symptomatic patients, asymptomatic patients were detected during routine screening. AIM: This study aims to determine the factors that affect antibody response and viral shedding in stool samples after natural exposure to the virus in residents and staff who recovered from COVID-19 before the vaccine was available. METHODS: This prospective cross-sectional study was conducted at the nation’s highest-capacity Residential and Nursing Home. Blood samples were collected between December 15, 2020 and January 15, 2021 from participating residents and staff for anti-SARS-CoV-2 antibody testing. Stool samples were obtained for SARS-CoV-2 PCR testing 2 months after COVID-19. The Social Sciences (SPSS) program version 15.0 was used for statistical analysis. The Mann–Whitney U test compared SARS‐CoV‐2 antibody concentration between two groups. RESULTS: Four hundred sixty-four (52.3%) residents and 424 (47.7%) staff participated. Entirely 259 (29.2%) participants were anti-SARS-CoV-2 IgG (+) and 255 (28.7%) were SARS-CoV-2 PCR (+). Both antibody and PCR positivity was detected in 196 (76.9%). In PCR (−) group, 63 (10.0%) participants were SARS-CoV‐2 IgG (+). Antibody titers were found highest in SARS-CoV-2 PCR (+) male residents. SARS-CoV-2 IgG titers were significantly high in SARS-CoV-2 PCR (+) and hospitalized participants regardless of age. Stool samples were obtained from 61(23.9%) participants and were found negative. CONCLUSION: A durable SARS-CoV‐2 IgG antibody response was monitored at least 9 months after the participants were diagnosed with COVID-19. SARS-CoV-2 antibody positivity was detected 76.9% in PCR (+) and 10.0% in PCR (−) participants. Knowing the duration of detectable antibodies is an important finding for developing disease prevention and public health strategies. Springer International Publishing 2022-07-12 2023 /pmc/articles/PMC9277604/ /pubmed/35829907 http://dx.doi.org/10.1007/s11845-022-03095-7 Text en © The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Eren-Kutsoylu, Oya Ozlem
Appak, Ozgur
Nazli-Zeka, Arzu
Omeroglu-Simsek, Gokcen
Tekin, Nil
Bayram, Basak
Sayiner, Ayca Arzu
Tanglay, Nesim
Avkan-Oguz, Vildan
Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination
title Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination
title_full Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination
title_fullStr Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination
title_full_unstemmed Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination
title_short Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination
title_sort evaluation of sars-cov-2 antibody persistence and viral spread in stool: a long-term care experience before covid-19 vaccination
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277604/
https://www.ncbi.nlm.nih.gov/pubmed/35829907
http://dx.doi.org/10.1007/s11845-022-03095-7
work_keys_str_mv AT erenkutsoyluoyaozlem evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination
AT appakozgur evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination
AT nazlizekaarzu evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination
AT omeroglusimsekgokcen evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination
AT tekinnil evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination
AT bayrambasak evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination
AT sayineraycaarzu evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination
AT tanglaynesim evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination
AT avkanoguzvildan evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination